USPTO serial 88004821
M MICROBIX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 25, 2024
- Examiner
- GOODWIN, KATRINA JOYE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with M MICROBIX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Mississauga, Ontario, CA
Mississauga, Ontario, CA
Mississauga, Ontario, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Richard M. LaBarge
Richard M. LaBarge MARSHALL, GERSTEIN & BORUN LLP233 SOUTH WACKER DRIVE, SUITE 6300CHICAGO, IL 60606UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemical agents for in vitro and in vivo scientific or diagnostic use, namely, viruses, bacteria, parasites, and purified and unpurified whole, fragmented, and fractionated pathogens and pathogenic organisms; Cells and cell culture derived products for in vitro or in vivo scientific or diagnostic use, namely, for production of organisms, proteins, nucleic acids, or cellular fractions used as reagents or antigens, test articles, or controls; antibodies and thrombolytics for in vitro scientific or research use; Biochemicals in the form of monoclonal antibodies for in vitro scientific use; Biochemicals in the form of monoclonal antibodies for research use; Active Pharmaceutical Ingredients to stimulate blood-clot dissolving processes; Microbial antigens and antisera for in vitro diagnostic use | ACTIVE | — |
| 005 | urokinase used to treat blood clots; Thrombolytic drugs, namely, plasminogen activating drugs and fibrinolytic drugs; urokinase preparations for the restoration of patency to central venous catheters obstructed by clotted blood or fibrin; urokinase preparations for treating pulmonary embolism; urokinase preparations for treating the lysis of acute pulmonary emboli and pulmonary emboli accompanied by unstable hemodynamics; urokinase preparations for treating thrombosis; urokinase preparations for treating coronary artery thrombosis; urokinase preparations for treating myocardial infarction; urokinase preparations for the lysis of thrombi; urokinase preparations for treating peripheral arterial and graft thromboembolic occlusion; urokinase preparations for treating deep vein thrombosis; urokinase preparations for treating pleural effusions; urokinase preparations for treating peripheral arterial occlusion; urokinase preparations for treating ischemic stroke; urokinase preparations for treating lower limb ischemia; test samples used in conjunction with laboratory diagnostics in the nature of biological or biochemical samples used to verify the reliability of laboratory equipment; test samples used in conjunction with assay methods in the nature of biological or biochemical assay samples used to verify the reliability of laboratory tests; Liquid, frozen and lyophilized inactivated, native pathogens, including whole and fragmented eukaryotes, prokaryotes, and viruses, independent and in host cells, all for in vitro and in vivo scientific or diagnostic use; inactivated, native pathogens, namely, liquid, frozen or lyophilized recombinant DNA and/or RNA preparations, either purified or within host organisms, in various buffers, singly and in combination, all for in vitro and in vivo scientific or diagnostic use; Positive controls, namely, reagents for use with nucleic-acid-based, immunologic, or other diagnostic tests to confirm proper test operation, and run in conjunction with patient samples run to confirm, assess, test, or verify the operation of the test method; proficiency test samples in the nature of biological test samples used to test the proficiency of technicians who use infectious disease diagnostics test systems to determine the pathogenic or biochemical content of samples; Diagnostic reagents in the nature of biotechnology products for medical and veterinary use, namely, micro-organisms for amplification controls; Diagnostic kits for in-vitro scientific and diagnostic use; Laboratory assay kits for scientific and diagnostic use; Biological material for scientific or diagnostic purposes, in the nature of serum and plasma from infected and disease state individuals used for verification and validation of human diagnostic assays for such infections and diseases; Biotechnology products for scientific or diagnostic purposes, namely, reagents and solutions in the nature of viruses, bacteria, fungi, parasites, and derivatives thereof used to research, develop, manufacture, and validate infectious disease diagnostic tests; biochemical products, namely, antibodies for scientific or research use; diagnostic reagents containing lyophilized microorganisms, and reagents containing lyophilized microorganisms all for in-vitro use and for use in biochemistry, clinical chemistry and microbiology; diagnostic reagents for scientific research use; diagnostic reagents for medical research use; diagnostic preparations for clinical laboratory use; diagnostic preparations for medical laboratory use; diagnostic preparations for medical research use; diagnostic preparations for scientific research use | ACTIVE | — |
| 009 | laboratory instruments for the detection pathogens and toxins in a biological sample for research use; Instruments for the processing of cells and cell derived materials, namely, flow cytometers and flow-based analyzers that detect and analyze nucleic acid content for scientific, laboratory, and general research use; laboratory instruments that detect pathogens in a biological sample for research use; Instruments for the processing of cells and cell derived materials | ACTIVE | — |
| 010 | automated flow cytometer sample introduction accessories used in conjunction with a flow cytometer to deliver biological and chemical samples from single test tubes and multiwell laboratory plates; medical apparatus for the automated analysis of cells in the nature of cytometers for medical diagnostic use; medical apparatus for the automated cytometric analysis of cells in the nature of cytometers for medical diagnostic use; medical apparatus in the nature of cytometers that detect atypia in cells for medical diagnostic use; medical apparatus for automated analysis of nuclear features for the detection of neoplasms and cancer and genetic conditions; apparatus for medical diagnostic uses in the nature of an automated flow cytometer sample introduction accessory, namely, a machine which is used in conjunction with a flow cytometer to deliver biological and chemical samples from single test tubes and multi-well laboratory plates | ACTIVE | — |
| 042 | Providing diagnostic testing services, laboratory tests; production for others of cells, cell lines, viruses, bacteria, and pathogens, proteins, or nucleic acids in whole or in part; Research and development services in the field of process technology used in the manufacture of vaccines; process technology services to be used in the manufacture of a vaccine; biological cell-selection services for biological research purposes; biological research services of delivering energy to a population of biological cells for the purpose of selecting desired cells and negatively selecting undesired cells | ACTIVE | — |
| 044 | Animal husbandry services; animal breeding services; sperm- and semen-sexing services in the nature of in vitro fertilization services; biological cell-selection services for medical purposes in the nature of in vitro fertilization services; medical services in the field of in vitro fertilization, namely, services of delivering energy to a population of biological cells for the purpose of selecting desired cells and negatively selecting undesired cells | ACTIVE | — |
| 045 | Licensing of process technology used in the manufacturing of vaccines | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Microbix Biosystems Inc.
- Other trademarks owned by Microbix Biosystems Inc.
- Other trademarks owned by Microbix Biosystems Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named M MICROBIX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 25, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 25, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 9, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 9, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 20, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 1, 2024 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Feb 22, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 20, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 20, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 20, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 20, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 30, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 30, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 30, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 28, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 28, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 28, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 25, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 25, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 24, 2023 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jul 26, 2023 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jul 26, 2023 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jul 26, 2023 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jul 6, 2023 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Dec 14, 2022 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Dec 14, 2022 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 14, 2022 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 12, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 12, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 12, 2022 | ALIE | ASSIGNED TO LIE | — |
| Dec 5, 2022 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jun 9, 2022 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jun 9, 2022 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jun 9, 2022 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| May 25, 2022 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Oct 20, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Oct 20, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Oct 20, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 12, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 12, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 5, 2021 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Apr 8, 2021 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Apr 8, 2021 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Apr 8, 2021 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Mar 24, 2021 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jun 12, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jun 12, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jun 12, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jun 10, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 10, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 5, 2020 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Dec 9, 2019 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Dec 9, 2019 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Dec 9, 2019 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Dec 4, 2019 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 15, 2019 | ALIE | ASSIGNED TO LIE | — |
| Apr 24, 2019 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 24, 2019 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 24, 2019 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 11, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 10, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 10, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 10, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 10, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 10, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 4, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 22, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 21, 2018 | NWAP | NEW APPLICATION ENTERED | — |